

The Value of the 340B Drug Pricing Program in Delaware



The 340B Drug Pricing Program is essential to helping Delaware's nonprofit hospitals, community health centers and other safety net providers that care for low-income and uninsured patients stretch scarce resources to provide more comprehensive care and support for their patients and communities.

Congress should **protect this vital program** to ensure Delaware's safety-net hospitals can continue to provide the care and community support needed for our most vulnerable populations and **prohibit drug companies from imposing restrictions** on 340B covered entities and their contract pharmacy arrangements. **DHA opposes federal proposals to create a 340B rebate model** that would change the program from an up-front discount to a back-end rebate, imposing significant cost and administrative burden on healthcare providers.

Here Are The Facts



Program is funded by drug company discounts. **NOT** taxpayer dollars.




340B provides **critical resources** to hospitals, federally qualified health centers and others safety-net providers.



Savings are **reinvested** back into communities for free health screenings, vaccination drives, preventative care in high-need areas, transportation, and more.



Rising costs of prescription drugs are driving growth in the 340B program. Delaware hospitals have faced a **54% increase in RX drug expenses** from FY20 to FY24.



\$85.3 Million

340B Program Benefits in FY24



Helped Support

More than \$833 Million

Community Benefit Activities

The **\$85.3 million** in savings from drug companies helps Delaware hospitals power a **more than \$833 million** investment in communities across the state.